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The neuropeptide galanin is widely expressed in the nervous system and has an important role in nociception. It has been
shown that galanin can facilitate and inhibit nociception in a dose-dependent manner, principally through the central nervous
system, with enhanced antinociceptive actions after nerve injury. However, following nerve injury, expression of galanin within
the peripheral nervous system is dramatically increased up to 120-fold. Despite this striking increase in the peripheral nervous
system, few studies have investigated the role that galanin plays in modulating nociception at the primary aﬀerent nociceptor.
Here, we summarise the recent work supporting the role of peripherally expressed galanin with particular reference to the dual
actions of the galanin receptor 2 in neuropathic pain highlighting this as a potential target analgesic.
1.Introduction
The 29-amino-acid neuropeptide galanin was ﬁrst identiﬁed
in porcine intestine [1] and later in the rat central nervous
system and intestine [2]. Since then galanin has been shown
to play important roles in a number of physiological pro-
cesses including cognition [3], feeding [4], and nociception
[5]. This paper will consider activation of galanin receptors
on primary aﬀerent nociceptors as a possible target for pain
treatment.
2. Galanin-HistoricalPerspectivesand
Spinal Nociceptive Processing
Galanin is expressed in many areas of the nervous system
involved in somatosensation including the dorsal root gan-
glia (DRG) and spinal cord [6, 7], and also in other CNS
regions such as the arcuate nucleus and periaqueductal grey
[8, 9]. In the peripheral nervous system, low levels of galanin
expression is present in the DRG of intact adult rodents,
with the peptide expressed in fewer than 5% of DRG sensory
neurons [10]. These galanin-expressing neurons belong to
a group of small diameter sensory aﬀerents that respond
to capsaicin [7, 11], which are characteristically C ﬁbre
nociceptors [12]. Galanin is now considered to be an injury-
response peptide, as it is dramatically upregulated in DRG
neurons in sciatic [6, 10] and saphenous nerve injury models
[13–17]. The original observations of galanin upregulation
after peripheral nerve injury strongly suggested a functional
role for galanin in nociception and that these actions were
through modulation of spinal nociceptive processing.
Priortotheidentiﬁcationandcharacterizationofgalanin
receptors in the central nervous system, functional studies
demonstrated that galanin could modulate spinal nocicep-
tive reﬂexes. Behaviourally, intrathecal galanin administra-
tion was initially reported to have diﬀerential eﬀects on
thermal and mechanical nociception in the normal ani-
mal; thermal responses were inhibited whereas mechanical
responses were enhanced [18, 19]. Numerous further studies
resulted in the recognition that galanin has diﬀerential
actions on spinal nociceptive processing, in that low galanin
concentrations exert pronociceptive [20–23]a n dh i g h e r
concentrations lead to antinociceptive eﬀects [24, 25]. In
contrast, in nerve-injured rodents, intrathecal galanin has2 Pain Research and Treatment
predominantly antinociceptive actions at the spinal level,
acting on a greater number of neurons, and these actions are
more pronounced than those seen in na¨ ıve animals [26–32].
These apparently conﬂicting spinal actions of galanin
at diﬀerent concentrations are thought to be due to the
diﬀerential distributions, and/or activation of the galanin
receptor subtypes. To date, three galanin G-protein-coupled
receptor subtypes have been identiﬁed, galanin receptor
(GalR) 1 [33], GalR2 [34], and GalR3 [35]. Galanin binding
is abundant in the superﬁcial laminae of the dorsal horn,
being localized to GABA and glycine containing inhibitory
interneurons [36]. The lack of speciﬁc antibodies against the
galanin receptors [37] has hampered localisation attempts,
but GalR1 mRNA is abundant in the superﬁcial laminae
of the dorsal horn [38, 39], in glutamatergic neurons [40].
GalR2 and GalR3 mRNA are found in a very small number
of superﬁcial dorsal horn neurones and in lamina X, and
both cell numbers and intensity of expression are very low
in comparison to GalR1 in the same areas [38, 41], and the
type(s) of neurones on which these receptors are expressed
are unknown.
Galanin has actions at both pre- and postsynaptic sites in
the dorsal horn [27]( Figure 1). Galanin exerts presynaptic
inhibition of neurotransmitter release, through activation of
presynaptic GalR2, reducing primary aﬀerent input into the
dorsal horn [25, 42]. Activation of postsynaptic GalR1 in
superﬁcial dorsal horn laminae [38]l e a d st oar e d u c t i o n
in postsynaptic neuronal excitability through activation of
inward rectifying potassium currents [42]. Central sensitisa-
tion is key to the observed behavioural changes consequent
to peripheral nerve injury [43], and galanin reduces central
sensitisation of spinal neuronal circuits [44], particularly
after nerve injury [44, 45]. There are also reports of
entirely excitatory (pronociceptive) eﬀects of galanin on
wide dynamic range spinal neurons [20], possibly mediated
throughGalR2[23].Dataderivedfromstudiesonintrathecal
administration of the galanin fragment, Gal2-11, which is
an agonist for GalR2/3, and as there is very little or no
GalR3 expressed, indicates that many of the concentration-
dependent eﬀects of intrathecal galanin are exerted through
GalR2,despitetherelativelysmallnumbersofspinalneurons
expressing GalR2 mRNA [23].
The contributions of diﬀerent GalR subtypes to spinal
nociceptive processing are still unclear, and, unfortunately,
the development of GalR knockout (KO) animals has not
greatly clariﬁed this area [53]. GalR1 knockout animals have
only subtle diﬀerences from wild types [54], possibly as a
result of altered expression of GalR2 and GalR3 in these
animals [54, 55]. Intact GalR2 KO animals have no observ-
able nociceptive phenotype, and the nociceptive responses to
exogenous galanin have not been investigated in these GalR2
KO animals. Pharmacological investigation had originally
suggested that GalR2 may mediate the pronociceptive eﬀects
of spinal galanin and that, after nerve, injury GalR1 may
underpin the antinociceptive actions [23].
An additional layer of complexity arises from the intra-
cellular signalling of the galanin receptors, as the second
messenger cascades activated give rise to diﬀerent functional
outcomes. All the reported galanin receptors are known to
couple to Gi/o andinhibitadenylylcyclaseactivity.GalR1and
GalR3 activation then results in neuronal hyperpolarization,
as a result of increased potassium conductance. GalR2, how-
ever, can couple to Gi/o and Gq [56]; activation of the latter G
protein results in activation of the phospholipase C-protein
kinase C pathway [57], which appears to be essential to the
GalR2 mediated pronociceptive eﬀect [58]. Activation of Gi
and Gq proteins is fundamental to nociceptive processing,
resulting in anti- and pronociceptive eﬀects, respectively,
when activated through diﬀerent GPCRs, in the P2Y family
[59]. This suggests that diﬀerent G protein activation by
GalR2 may result in pro- or antinociceptive downstream
eﬀects. In other galanin receptor systems, opposing eﬀects
can be evoked by activation of these G-proteins by the
same receptor, for example, in a model of epilepsy, GalR2-
Gi activation is antiepileptic and GalR2-Gq is proepileptic
[60]. In addition, diﬀerent agonist concentrations have also
been reported to exert opposing eﬀects in diﬀerent receptor
systems, for example, low concentrations of angiotensin II
lead to an inhibition of vesicular neurotransmitter release
whereas high concentrations potentiate exocytosis [61]. It
is hypothesised that when galanin expression rises to high
levels within the peripheral nervous system, such as after
peripheral nerve injury, and is released into the dorsal
horn [46, 62], GalR2 activation switches from a Gq- (low
galanin concentration) to a Gi/o- dependent pathway (high
galanin concentration), that is from a pro- to antinociceptive
signalling pathway [59].
Thus, the biphasic concentration-dependent actions of
galanin on spinal nociception may occur through a com-
bination of activation of diﬀerent galanin receptors (GalR1
and GalR2), expressed on diﬀerent dorsal horn neurons
(inhibitory or excitatory), or acting at diﬀerent sites (pre-
and post-synaptic), and/or through activation of diﬀerent
signal transduction pathways (which are concentration-
dependent GalR2 activation of either Gi/o or Gq second
messenger pathways (Figure 1).
3. DirectActions of Galaninon Primary
Afferent Nociceptors
Binding and expression studies have shown that GalR1
and GalR2 are found in DRG neurons [63–65], and these
receptors are functional on the central terminals of primary
aﬀerents [25, 42]. Little or no GalR3 mRNA expression is
found in either the DRG or spinal cord [66, 67]. Given that
proteinssynthesisedbyDRGneuronsareusuallytransported
peripherally in addition to centrally, these observations raise
the possibility that galanin may modulate the function of
nociceptors by actions on their peripheral, in addition to
their central terminals. Galanin expression is not limited to
the nervous system but has also been identiﬁed in nonneu-
ronal peripheral tissues such as keratinocytes, sweat glands,
macrophages, and blood vessels [68]. Galanin released from
such peripheral sites could therefore modulate peripheral
nociceptive function, for example, keratinocytes in the skin
have been demonstrated to alter primary sensory neuronal
function through release of various mediators [69].Pain Research and Treatment 3
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Figure 1: Putative galanin-mediated neuronal pro- and antinociceptive mechanisms in the dorsal horn of the spinal cord. (a) In the na¨ ıve
animal, GalR1 and GalR2 are expressed on the central terminals of a large proportion of small diameter TRPV1 expressing C ﬁbres.
Galanin itself is expressed at very low levels in a small number of neurons. Peripheral activation of nociceptive C ﬁbre aﬀerents leads to
neurotransmitter release (e.g., glutamate) at the ﬁrst synapse in the superﬁcial dorsal horn in the spinal cord, including galanin release (ﬁlled
circles)[46].Intheuninjuredstate,galaninreleaseislowatthissynapse.Evokedgalaninreleaseorexogenousgalaninispostulatedtoactivate
presynaptic GalR2 (solid arrow). This stimulates signalling through Gq in the central terminals, which then regulates both the sensitisation
andexpressionofTRPV1andhenceaﬀerentsensitivity[11,47].Inaddition,Gq actsonP/Q typecalciumchannels[11],whichwouldserveto
enhance neurotransmitter release (e.g., glutamate, open circles), enhancing excitation of postsynaptic neurons. Postsynaptic neurons express
bothGalR1andGalR2.GalR1isexpressedonbothexcitatory(glutamatergic)andinhibitory(GABA-andglycinergic)postsynapticneurons,
andactivationreducesexcitabilityoftheseneuronsthroughactionsonpotassiumchannels(checkeredboxes).PostsynapticGalR2activation
is postulated to result in the low concentration pronociceptive eﬀects of galanin [23]. The net eﬀect of the activation of GalR1 and GalR2 on
spinal nociceptive processing will diﬀer depending on the degree of presynaptic activation and whether excitatory or inhibitory postsynaptic
neurons are aﬀected. GalR1 is also expressed on DRG neurons, but whether presynaptic eﬀects of galanin are also mediated through GalR1
is not yet known as there is no evidence that these receptors are functional. Dashed lines indicate minimal eﬀects on the pathways shown.
(b) After nerve injury, galanin levels are massively upregulated in DRG neurons. Up to 50% of neurons now express galanin and to a much
higher level, resulting in a 120-fold increase in DRG galanin expression. There is also a small increase in galanin expression in the dorsal
horn, [13] where galanin is largely found in inhibitory neurons [48, 49]. Spontaneous ﬁring increases in primary aﬀerents, and galanin
release into the dorsal horn is increased after both nerve injury [46] and nociceptor stimulation [46]. Spinal GalR levels are only minimally
altered under these conditions. Increased galanin release into the dorsal horn would increase basal activation of presynaptic GalR2, which
underhighgalaninconcentrationscouplestoGi/o.TRPV1sensitisationisthereforereduced.Gi/o couplingalsostopstheactivationofcalcium
channels thereby greatly reducing glutamate release and hence nociceptive input to the dorsal horn [25]. In addition, galanin exerts greater
postsynaptic eﬀects, eﬀectively reducing central sensitisation [27, 44, 45]. In nerve injury, therefore, increased endogenous or exogenous
galaninenhancestheseactionsandresultsinantinociception.(c)(Inset)Aschematicrepresentationofthegalaninconcentration-dependent
system. Pronociceptive actions are exerted by low-concentration galanin when GalR2 couples to Gq. This then activates the protein kinase
C-phospholipase C pathway to lead to enhanced nociceptor excitability and behavioural hypersensitivity. When galanin concentrations are
higher, for example, after nerve injury, GalR2 couples to Gi, reducing nociceptor excitability through inhibition of peripheral sensitisation.
Galanin enhances the excitability of TRPV1-expressing
nociceptive DRG neurones both in vitro [11]a n din vivo
[58]. Exogenous galanin, delivered in the periphery, has
been shown to modulate the properties of primary aﬀerent
nociceptors in vivo, in a manner similar to that seen in
the spinal cord, that is, galanin exerts both facilitatory
and inhibitory eﬀects on primary aﬀerent nociceptors [27,
51, 70]. We have shown that the opposing actions of
galanin on primary aﬀerent nociceptors are, as in the
spinal cord, concentration dependent. Low concentrations
of galanin sensitise primary aﬀerent nociceptors in na¨ ıve
rodents, resulting in decreased mechanical activation thresh-
olds and increased mechanically evoked activity, whereas
higher concentrations inhibit nociceptor responses. These
actions are of similar magnitude in nerve-injured animals
[51]. The concentration-dependent eﬀects of galanin on
primary aﬀerents are mediated through peripheral GalR2,
as both the reduction in threshold and increase in evoked
activityareseenonlyinaﬀerentsexpressingfunctionalGalR2
[51]. Similar concentration-dependent actions of galanin
have been reported in DRG neurons in vitro, for example,
inhibition of DRG P/Q calcium channel activity through4 Pain Research and Treatment
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Figure 2:MechanicalresponsesofacharacterisedsubsetofCﬁbrenociceptoraﬀerentsexpressingfunctionalgalaninreceptors,inintactand
PSNI-injuredrats.NociceptorsweredeﬁnedasthoseaﬀerentswithavonFreymechanical thresholdgreaterthan1g[50].Functionalgalanin
receptors were identiﬁed in individual aﬀerents by their response to close arterial injection of galanin and Gal2-11. Functional receptors were
deemedtobepresentifthemechanicallyevokedresponsewasincreasedintheaﬀerentaftergalaninorGal2-11,asattheconcentrationsusing
(close intra-arterial injection 0.1mM) aﬀerent responses were facilitated in both na¨ ıve and nerve injured animals [51]. (a) High threshold
mechanoreceptive (nociceptive) aﬀerents in rats with a peripheral nerve injury [14, 52] with functional galanin receptors (NI GalR+ve)
had lower mechanical activation thresholds than those in uninjured rats (Intact GalR+ve). The thresholds were also lower in NI GalR+ve
aﬀerentscomparedtonociceptive aﬀerentsthatdidnotexpressfunctionalgalaninreceptors(NIandIntactGalR−ve) irrespective of whether
the animals had a peripheral nerve injury or not (∗∗∗P<0.001, Kruskal Wallis test with Dunn’s multiple comparison test, aﬀerent number
intact n = 50, PSNI n = 43). (b) Nociceptive aﬀerents from animals with nerve injury with functional GalR2 (NI GalR2+ve) also had lower
mechanical thresholds compared to those from na¨ ıve animals (Intact GalR2+ve). (∗P<0.05, Mann-Whitney test aﬀerent number intact =
23, PSNI = 13).
activation of GalR2 shows similar concentration dependence
[11, 71]. These ﬁndings therefore suggest that galanin
receptors, speciﬁcally GalR2, in primary aﬀerent nociceptors
are possible analgesic targets in vivo, as nociceptor properties
can be directly modulated by activation of peripheral GalR2.
4.Galanin,GalaninReceptors,and
Actions on Primary Afferent Nociceptors
Following Peripheral Nerve Injury
After a nerve injury, galanin expression is upregulated in the
peripheral nervous system and galanin release is enhanced
in the dorsal horn [46, 62]. The advent of knockout and
transgenic animals has allowed further examination of the
nociceptive role played by endogenous galanin after nerve
injury. This includes using galanin-promoter-driven nerve-
injury-inducedgalaninoverexpression[72]anddoxycycline-
induced suppression of galanin overexpression [73]. Overex-
pressionofgalaninpreventedthedevelopmentofmechanical
allodynia after nerve injury [51, 72], and allodynia was
reversed on doxycycline administration and, importantly,
reestablished on doxycycline withdrawal [73]. Study of
galanin knockout mice surprisingly revealed a neurotrophic
eﬀect of galanin acting through GalR2, as both galanin and
GalR2 knockout animals lost a speciﬁc subset of sensory
neurones [66, 74]; therefore, those nociceptive phenotypes
in these transgenic models cannot be interpreted. These
ﬁndings indicate a substantial contribution of albeit overex-
pressed, endogenous galaninto spinal nociceptive processing
in nerve injury, in that increased spinal galanin release can
alleviate nerve-injury-induced allodynia. Taken together, the
eﬀectsofgalaninoverexpressionindicatethatphysiologically,
endogenous galanin exerts antinociceptive actions under
conditionsinwhichnociceptiveprocessingisenhanced,such
as peripheral nerve injury [72, 75].
Despite the evidence that galanin can aﬀect the periph-
eralterminalsofprimaryaﬀerentnociceptors,mostworkhas
concentrated on the actions of galanin in the spinal cord,
on presynaptic nociceptor terminals and on postsynaptic
dorsal horn neurones. This is attributable to the key role of
central sensitisation in altered pain behaviours consequent
to nerve injury, and also because peripheral sensitisation
has long been thought to contribute little to neuropathic
pain. Recently, however, peripheral sensitisation has been
described in nerve injury models, including reduction in
primary aﬀerent activation threshold and the onset of
ongoing activity[50,52,76–78] and, importantly, in patients
with neuropathic pain [79, 80]. When identiﬁed subsets
of nociceptors are studied in inﬂammatory models, clear
reductions in mechanical activation thresholds, that is,
peripheral mechanical sensitisation, can be seen [50]. We
have shown that functional GalR2 expression is a marker for
those primary aﬀerents that become sensitised to mechanical
stimulation after nerve injury, that is, the aﬀerents that
express GalR2 after nerve injury are those that exhibit
peripheral mechanical sensitisation (Figure 2). This is not to
say that the action of galanin on primary aﬀerents results
in sensitisation and more that GalR2 is a possible target for
identiﬁcation and possible reversal of peripheral mechanicalPain Research and Treatment 5
sensitisation. Using galanin overexpressing (GalOE) mice,
we tested the hypothesis that increased endogenous galanin
expression after nerve injury might directly aﬀect the
properties of the peripheral nociceptors, rather than the
central processing of nociceptive inputs. In GalOE animals
with peripheral nerve injury, nociceptive behaviours did not
change, reduction in primary aﬀerent nociceptor threshold
was not seen, and nociceptor ongoing activity did not
develop, although all of these changes were seen in wild
type controls [51]. Our ﬁndings, therefore, indicate that
GalR expressing primary aﬀerent nociceptors represent at
least a proportion of the population of peripheral neurons
that show peripheral sensitisation after nerve injury and that
increased endogenous galanin can prevent the development
of peripheral sensitisation.
In order for GalR2 in primary aﬀerent nociceptors to
represent an eﬀective analgesic target, activation of the
receptor must also be eﬀective in chronic pain states, which
is suggested by the results described above. The data in the
na¨ ıve animal show that galanin can have facilitatory, in addi-
tion to inhibitory actions on primary aﬀerents, depending
on the concentration [27, 51, 70]. Facilitation would, of
course, be detrimental in a chronic pain state. As described,
the galanin system is highly plastic following peripheral
nerve injury [26, 29], and, under these conditions, the
inhibitory actions of both spinal [31] and peripheral galanin
appearenhanced[27].Determinationofthecontributionsof
speciﬁc GalR to peripheral sensitisation in neuropathy will
be fundamental to the development of a potential peripheral
GalR-targeted analgesic. Little, however, is known about
GalR regulation in peripheral nociceptor terminals after
nerve injury, due to the lack of speciﬁc GalR antibodies.
GalR1andGalR2mRNAsaredownregulatedinDRGsensory
neurons after peripheral nerve axotomy [66, 81], although
the decrease in GalR2 is less profound [82].
Functionally, behavioural studies in GalR knockout mice
do not give speciﬁc information on receptor function
in peripheral nociceptors. Using methods that speciﬁcally
study peripheral aﬀerents, we have shown that peripheral
activation of GalR2 modulates C ﬁbre nociceptor function
in nerve injured rats and shows a concentration dependence
that is similar to that seen in na¨ ıve animals [51]. This is
in contrast to the previously reported enhancement of the
antinociceptive eﬀect of galanin at the spinal level in neuro-
pathic pain [27, 29]. While these ﬁndings might suggest that
peripheral GalR may not represent good analgesic targets,
we suggest that in pathological conditions when endogenous
galanin levels would be dramatically increased, further GalR
activation would be hypothesised to be more likely to drive
GalR-Gi/o- mediated signalling and would therefore result in
anti-nociceptive actions.
This paper highlights peripheral GalR2 as a potential
peripheral analgesic target. GalR2 activation by high concen-
tration galanin inhibits primary aﬀerent nociceptor activity
and thereby reduces nociceptive input to the spinal cord.
Once speciﬁc GalR2 pharmacological tools with favourable
c h a r a c t e r i s t i c ss u c ha sl o n gin vivo half-lives are developed,
peripheral antinociceptive GalR2-mediated mechanisms can
be fully characterized. GalR2 may represent a therapeutic
target that may be eﬀective for the alleviation of neuropathic
pain.
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